Display options
Cite
Di H, Wu H, Gao Y, et al. Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug Dev Ind Pharm. 2016;42(12):2038-2043doi: 10.1080/03639045.2016.1190743.
Di, H., Wu, H., Gao, Y., Li, W., Zou, D., & Dong, C. (2016). Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug development and industrial pharmacy, 42(12), 2038-2043. https://doi.org/10.1080/03639045.2016.1190743
Di, Huifeng, et al. "Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy." Drug development and industrial pharmacy vol. 42,12 (2016): 2038-2043. doi: https://doi.org/10.1080/03639045.2016.1190743
Di H, Wu H, Gao Y, Li W, Zou D, Dong C. Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug Dev Ind Pharm. 2016 Dec;42(12):2038-2043. doi: 10.1080/03639045.2016.1190743. Epub 2016 Jun 01. PMID: 27184819.
Copy Download .nbib Format: NLM
Share it on

Drug Dev Ind Pharm. 2016 Dec;42(12):2038-2043. doi: 10.1080/03639045.2016.1190743. Epub 2016 Jun 01.

Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy.

Drug development and industrial pharmacy

Huifeng Di, Haiyan Wu, Ying Gao, Weihua Li, Dongna Zou, Chuanhai Dong

Affiliations

  1. a Department of Pharmacy , Laiwu City People's Hospital , Laiwu , China ;
  2. b Department of Pharmacy , Shandong Provincial Hospital Affiliated to Shandong University , Ji'nan , China.

PMID: 27184819 DOI: 10.1080/03639045.2016.1190743

Abstract

CONTEXT: Combination anticancer therapy is promising to generate synergistic anticancer effects, to maximize the treatment effect and to overcome multi-drug resistance. Nanostructured lipid carriers (NLCs), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers.

OBJECTIVE: The aim of this study is to construct novel NLCs as nanocarriers for co-delivery of doxorubicin (DOX) and cisplatin (CDDP) to treat breast cancer.

METHODS: DOX and CDDP loaded NLCs (D-C-NLCs) were prepared by the solvent diffusion method. The in vitro cytotoxicity and synergistic studies of different formulations were evaluated on human breast cancer cells (doxorubicin resistant) (MCF-7/ADR cells). In vivo anti-tumor effects were observed on the murine bearing MCF-7/ADR cells model.

RESULTS: D-C-NLCs showed the highest cytotoxicity and synergistic effect of two drugs in tumor cells in vitro. The in vivo study revealed the greatest anti-tumor activity than the other formulations in the breast cancer model.

CONCLUSION: The constructed NLCs could be used as a novel carrier for co-delivery of DOX and CDDP for breast cancer therapy. D-C-NLCs could be a promising targeted and combinational therapy nanomedicine.

Keywords: Breast cancer; co-delivery system; combination chemotherapy; multi-drug resistance; nanostructured lipid carriers

Publication Types